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Abstract
Transthyretin (TTR) protects against A-Beta toxicity by binding the peptide thus inhibiting its aggregation. Previous work
showed different TTR mutations interact differently with A-Beta, with increasing affinities correlating with decreasing
amyloidogenecity of the TTR mutant; this did not impact on the levels of inhibition of A-Beta aggregation, as assessed by
transmission electron microscopy. Our work aimed at probing differences in binding to A-Beta by WT, T119M and L55P TTR
using quantitative assays, and at identifying factors affecting this interaction. We addressed the impact of such factors in
TTR ability to degrade A-Beta. Using a dot blot approach with the anti-oligomeric antibody A11, we showed that A-Beta
formed oligomers transiently, indicating aggregation and fibril formation, whereas in the presence of WT and T119M TTR
the oligomers persisted longer, indicative that these variants avoided further aggregation into fibrils. In contrast, L55PTTR
was not able to inhibit oligomerization or to prevent evolution to aggregates and fibrils. Furthermore, apoptosis assessment
showed WT and T119M TTR were able to protect against A-Beta toxicity. Because the amyloidogenic potential of TTR is
inversely correlated with its stability, the use of drugs able to stabilize TTR tetrameric fold could result in increased TTR/A-
Beta binding. Here we showed that iododiflunisal, 3-dinitrophenol, resveratrol, [2-(3,5-dichlorophenyl)amino] (DCPA) and [4-
(3,5-difluorophenyl)] (DFPB) were able to increase TTR binding to A-Beta; however only DCPA and DFPB improved TTR
proteolytic activity. Thyroxine, a TTR ligand, did not influence TTR/A-Beta interaction and A-Beta degradation by TTR,
whereas RBP, another TTR ligand, not only obstructed the interaction but also inhibited TTR proteolytic activity. Our results
showed differences between WT and T119M TTR, and L55PTTR mutant regarding their interaction with A-Beta and prompt
the stability of TTR as a key factor in this interaction, which may be relevant in AD pathogenesis and for the design of
therapeutic TTR-based therapies.
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Introduction
Alzheimer’s disease (AD) is nowadays responsible by 50 to 80
percent of dementia cases [1] and is mainly characterized by two
types of lesions: neurofibrillary tangles (NFTs) and neuritic
plaques. NFTs [2] are bundles of abnormal filaments composed
of highly phosphorylated tau protein [3]. Neuritic plaques are
extracellular amyloid deposits found in the brain and are mainly
constituted by beta-amyloid (A-Beta) peptide. Accumulation of A-
Beta is due to disregulated proteolytic processing of its precursor,
the Amyloid Precursor Protein (APP).
Schwarzman et al. described that normal cerebrospinal fluid
(CSF) inhibits amyloid formation [4] and concluded that
transthyretin (TTR) was the major A-Beta binding protein in
CSF, leading to a decrease in the aggregation state of the peptide
[4]. More recently it has been shown that deletion of the TTR
gene in a mouse APP transgenic model results in increased of A-
Beta deposition [5]. Our group characterized the TTR/A-Beta
interaction showing that TTR is capable of interfering with A-Beta
fibrilization by both inhibiting and disrupting fibril formation [6].
We also demonstrated that TTR, either recombinant or isolated
from human sera, was able to proteolytically process A-Beta.
Furthermore, A-Beta new peptides (1–14) and (15–42), generated
upon cleavage by TTR, showed lower amyloidogenic potential
than the full length counterpart [7].
TTR is a homotetramer and it is thought that the first step in
the cascade that results in amyloid formation, is the dissociation of
the tetramer into monomers [8]. TTR is responsible for the
transport of thyroxine (T4) and retinol, through binding to the
retinol binding protein (RBP). The four monomers within a TTR
tetramer, form an open channel where T4 binds [9,10] while
retinol interacts with only one of the dimers, at the surface [11].
TTR, when mutated, is associated to another amyloidotic
disorder, Familial Amyloid Polyneuropathy (FAP), characterized
by the extracellular deposition of TTR in several organs with a
special emphasis in the peripheral nerve.
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Particular mutations in the protein lead to instability of the
native fold, increasing its propensity to precipitate and aggregate.
For instance, it was suggested that mutated L55P TTR
significantly alters tetramer stability and increases amyloidogeni-
city [12]. The authors described that L55P TTR tetramer was
more unstable than the WT TTR and that the ability of L55P
TTR to develop to an amyloidogenic intermediate occurred at
higher pHs than the wild-type protein; this could explain why
some TTR variants form amyloid fibrils, while the WT TTR
remains stable and nonamyloidogenic [12]. Furthermore, Longo
Alves et al. compared the stability and clearance of V30M TTR
and T119M TTR and described that the more stable properties of
T199M variant could be involved in the protective clinical effect of
the T119M mutation in FAP. Baures et al. and Oza et al.,
demonstrated several small compounds sharing molecular struc-
tural similarities with TTR natural ligand2 T42 that can bind in
the T4 binding sites, proposing them as inhibitors of TTR fibril
formation in vitro [13,14]. In addition and related to the
stabilization of TTR, Costa et al. described that TTR mutations,
such T119M, Y78F, V30M and L55P bound differently to A-Beta.
Additionally, an inverse relation between the amyloidogenic
potential of TTR and the affinity to A-Beta peptide was suggestive
of a direct relationship with TTR stability [6].
In the present work we further explore TTR/A-Beta interac-
tion, in particular the influence of TTR stability and ligands, on
binding properties.
Materials and Methods
TTR production and purification
Recombinant TTRs were produced in a bacterial expression
system using Escherichia coli BL21 [15] and purified as previously
described [16]. Briefly, after growing the bacteria, the protein was
isolated and purified by preparative gel electrophoresis after ion
exchange chromatography. Protein concentration was determined
using the Bio-Rad assay kit (Bio-Rad), using bovine serum albumin
(BSA) as standard.
Production of A-Beta species
The peptide was purchased from Genscript, dissolved in
Hexafluoroisopropanol (HFIP) and kept at room temperature
overnight. The HFIP was removed under a stream of nitrogen and
the residue was then dissolved in Dimethyl sulfoxide (DMSO) at
2 mM. For experiments, A-Beta was diluted in the buffers
mentioned below at the indicated concentrations.
A11 antibody assay
Soluble A-Beta alone (100 mM) or mixed with WT TTR,
T119M or L55P TTR (10 mM), or TTR alone, were incubated at
37uC and aliquots of 0.45 mg A-Beta were removed over time and
immobilized onto a nitrocellulose membrane. Detection of
oligomers was performed using the A11 antibody (1:500,
Biosource), followed by an anti-rabbit HRP (horseradish perox-
idase) conjugate (1:500) as the secondary antibody. Detection was
performed with ECLH (enhanced chemiluminescence; GE Health-
care).
Cell culture and caspase-3 assay
SH-SY5Y cells (human neuroblastoma cell line; (European
Collection of Cell Cultures)) [17], were propagated in 25-cm flasks
and maintained at 37uC in a humidified atmosphere of 95% and
5% Carbon dioxide (CO2) and grown in MEM/F12 (1:1) (Lonza)
supplemented with 15% fetal bovine serum (FBS) (Gibco BRL).
Activation of caspase-3 was measured using the CaspACE
fluorimetric 96-well plate assay system (Sigma), following the
manufacturer’s instructions. Briefly, 80% confluent cells were
cultured in 6-well plates and were grown for 24 hours. Then, the
medium was renewed 3–5 hours later, and 10 mM A-Beta peptide,
previously incubated with and 2 mM TTR, WT, T119M or L55P,
for 48 hours at 4uC in F12 media (Lonza), was added to the cells.
Subsequently, each well was trypsinized and the cell pellet was
lysed in 100 ml of hypotonic lysis buffer (Sigma). 40 ml of each cell
lysate was used in duplicates for determination of caspase-3
activation. The remaining cell lysate was used to measure total
cellular protein concentration with the Bio-Rad protein assay kit
(Bio-Rad), using BSA as standard. Experiments were repeated at
least twice; values shown are the mean of duplicates.
Chemical Compounds
Tri-iodophenol (TIP), Flufenamic Acid (Fluf), Diflunisal (Dif),
Resveratrol (Resv), 2-((3,5-Dichlorophenyl)amino)benzoic acid
(DCPA), Dinitrophenol (DNP), 4-(3,5-difluorophenyl) (DFPB),
Genistein, Epigallocatechin gallate (EGCG) and thyroxine (T4)
were from Sigma. The diflunisal derivative, iododiflunisal (I-Dif,
Mr 376.1) was kindly provided by Dr. Gregorio Valencia, CSIC,
Barcelona [18]. Retinol Binding Protein (RBP) was isolated from
serum by affinity in a TTR column and saturated with 3.3 mg/ml
all-trans retinol (Sigma) in ethanol as follows: (i) 25 ml of all-trans-
retinol were incubated with 800 ml of RBP (1 mg/ml) at 37uC in
the dark for 1 h; and (ii) excess retinol was separated from RBP by
gel filtration in 10-ml Biogel P-6 DG columns (Bio-Rad)[19].
Competition binding assays
Recombinant TTRs were iodinated with Na125I (NEN) using
the Iodogen (Sigma) method, following the supplier’s instructions.
The reaction was desalted by Sephadex G50 gel filtration; 96 well
plates (Maxisorp, Nunc) were coated with A-Beta (5 mg/well) in
coating buffer (Na2CO3/NaHCO3 pH 9.0) and incubated over-
night at 4uC. Unoccupied sites were blocked with 5% non-fat
dried milk in PBS for 2 hours at 37uC. For competition studies,
different concentrations of cold TTR (06 to 1006molar excess),
alone or pre-incubated for 12 hours with a 56 molar excess of
RBP or different compounds included: TIP, Fluf, Dif, I-Dif, Resv,
DCPA, DNP, DFPB, Genistein and EGCG were used and mixed
with a constant amount of 125I-WT TTR (500000 cpm) and
incubated for two hours at 37uC. Binding was determined after
five washes in ice cold phosphate-buffered saline with 0.05%
tween20 (PBS-T). Then, 0.1 ml of elution buffer (NaCl 0.1 M
containing Nonidet P40 (NP40) 1%) was added for 5 minutes at
37uC and the contents of the wells aspirated and counted in a
rackgamma counter. Experiments were repeated at least twice in
quadruplicates.
A-Beta proteolysis assay
A fluorogenic peptide encompassing 6 residues of the A-Beta
peptide sequence containing one of the TTR cleavage sites
previously described [7] was used (Abz-VHHQKL-EDDnp,
Genscript); this substrate is an internally quenched fluorescent
peptide in which Abz (ortho-aminobenzoic acid) is the fluorescent
donor and EDDnp [N-(ethylenediamine)-2,4-dinitrophenyl amide]
is the fluorescent quencher. Hydrolysis of the fluorogenic substrate
was monitored by measuring fluorescence at lem= 420 nm and
lex = 320 nm in a fmax plate reader (Molecular Devices). The
kinetics of the reaction was followed for 1 h at 37uC. To determine
the effect of different TTR ligands on its ability to cleave A-Beta
peptide, 5 mM of TTR was pre-incubated (for 1 hour) with the
compounds described above (till 10 fold molar excess) at 37uC with
50 mM Tris pH 7.5 and then 5 mM of substrate was added in a
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final volume of 100 mL. Experiments were repeated at least three
times.
Assessment of tetrameric TTR stability by IEF (isoelectric
focusing) in semi-denaturing conditions
The conditions used for the IEF of plasma TTR have been
described previously by Altland et al. [20] and Almeida et al. [18].
Briefly, 12 mg of recombinant L55P TTR were incubated at 4uC
overnight, with 10 mM solution of the tested compounds. The
preparations were then subjected to native PAGE to isolate TTR.
The gel band containing TTR was excised and subjected to IEF in
a gel with 4 M urea and 5% ampholytes (pH 4–6.5) at 1200 V for
6 h. Proteins in the gel were stained with Coomassie Blue. These
semi-denaturing conditions allow the visualization of bands
corresponding to the TTR monomer and tetramer and also to
an oxidized form of the monomer. Gels were scanned and bands
were quantified using the Quantity One program. Experiments
were repeated at least two times and data shown are representative
of the results obtained.
Statistical analysis
All data were expressed as mean values 6 standard error of the
mean (SEM). One way ANOVA with Bonferroni’s post-test was
performed using GraphPad Prism, version 5.04 for Windows,
GraphPad Software, San Diego California USA, www.graphpad.
com. Values of p,0.05 were considered to be significant.
Results
1. Differences in binding to A-Beta peptide by WT, T119M
and L55P TTRs using quantitative assays
a. Effect on A-Beta peptide oligomerization. Previous
results indicated that TTR mutants bind differently to A-Beta
peptide, with the following trend: T119M . WT . V30M $
Y78F . L55P TTR, suggesting that TTR amyloidogenecity
influences its binding to the peptide; at the level of A-Beta
aggregation, we did not detect any differences between TTR
mutants, as both non-amyloidogenic and amyloidogenic variants
were able to prevent A-Beta fibrilization with approximately the
same extent, as evaluated by transmission electron microscopy
(TEM) [6]. In the present work, we further compared if different
TTR variants differently affect A-Beta fibrillogenesis, making use
of a dot blot assay with the A11 antibody, described as specific for
oligomeric species. This antibody has the ability to recognize an
amyloidogenic conformation present in intermediate species from
different amyloidogenic precursors; however, it does not recognize
their soluble, aggregated or fibrillar counterparts [21].
Soluble A-Beta alone or mixed with WT, TT119M or L55P
TTR mutant were incubated at 37uC and aliquots of 0.45 mg were
removed over time and immobilized onto a nitrocellulose
membrane. For the incubation of A-Beta alone, detection with
the A11 antibody showed the presence of A-Beta oligomers
starting at day 0 (not shown) which continued until day 8
(figure 1A). At day 10 the A11 signal disappeared completely,
suggesting that A-Beta oligomers evolved to other species such as
aggregates and fibrils which are not recognized by this antibody.
Co-incubation of the peptide with WT TTR produced a different
profile as the presence of oligomers was prolonged until at least
day 10 (last time point analysed) (figure 1A), indicative that the
WT protein avoided further aggregation of the peptide into fibrils,
by arresting the oligomer stage. TTR T119M, a protective
mutation in FAP patients, was also able to avoid further
aggregation of A-Beta peptide, producing an A-Beta profile
similar to the one treated with WT TTR.
On the contrary, L55P TTR was not able to inhibit
oligomerization nor to prevent evolution to aggregates and fibrils
(figure 1A), resulting in a fainter A11 signal in the last days
analyzed, indicating that A-Beta aggregated and evolved to
aggregates and fibrils. The same amount of WT, T119M and
L55P TTR were also incubated alone and analysed over time, as
above; detection with the A11 antibody revealed no reaction
confirming that the signal observed previously was from A-Beta
(not shown).
b. Effect on A-Beta toxicity. We next analyzed the effect of
TTR on A-Beta toxicity, using the same TTR variants, WT
T119M and L55P TTR. Caspase 3 activation was measured in
SH-SY5Y cells treated with A-Beta previously oligomerized for
48 hours, alone or in the presence of the selected TTR variant;
controls of TTRs alone were also included. Figure 1B shows that
WT TTR was able to prevent the toxicity associated to A-Beta
oligomers, as previously shown [6]; Moreover, the non-amyloido-
genic variant T119M also significantly inhibited caspase 3
activation, therefore preventing A-Beta toxicity, whereas A-Beta
pre-incubated with L55P TTR produced similar levels of active
caspase 3 as found in cells treated with A-Beta alone.
Altogether, the oligomerization and toxicity studies indicated
differences between the non-amyloidogenic TTR variants WT
and T119M, and the highly amyloidogenic mutant L55P TTR
regarding their ability to interfere with A-Beta peptide amyloido-
genic properties.
2. Importance of TTR stability in its interaction with A-
Beta peptide
a. Effect of TTR stabilizers in A-Beta binding. We tested
whether small compounds known to stabilize the TTR tetrameric
fold should restore the capacity of TTR to bind A-Beta, in
particular the L55P TTR variant with low binding capacity. To
test this hypothesis, we used competition binding assays as this
technique allows not only the assessment of the interaction
between molecules but also to infer on the strength of the
interaction. We started by using Dif, a non-steroid anti-inflam-
matory (NSAIDs), and its derivative, I-Dif. The latter has been
shown to highly stabilize the TTR tetramer structure, in vitro and ex
vivo, whereas Dif could only produce a mild effect, under the same
conditions. [18].
Using competition binding assays after pre-incubation of WT
TTR with the referred drugs, we observed that the presence of I-
Dif improved TTR binding to A-Beta peptide, whereas Dif, on the
contrary, worsened the binding (figure 2). Other small compounds
known to stabilize the TTR tetrameric fold such as Resv, DNP,
DCPA, DFPB, EGCG, flufenamic acid, genistein, benzo and TIP
[22] were also assayed but we did not observe improvement in the
WT TTR/A-Beta binding (data not shown).
We reasoned that drugs with more modest effects, not as striking
as I-Dif, may not produce visible impact on WT TTR/A-Beta
binding, but could produce a profound effect if applied to the
L55P TTR variant. We started by performing IEF assays to
investigate if this variant was also stabilized by the same
compounds as the WT and V30M counterparts did [22,23], and
found no differences in the degree of stabilization among the three
proteins (i.e tetramer/monomer ratio) for the different tetramer
stabilizing drugs (figure 3A). We then repeated the A-Beta binding
assays with L55P and, as expected, this variant bound poorly to
the peptide since no differences in binding were observed in the
presence of the different cold TTR concentrations used (Figure 3A,
white bars). Nevertheless, in our assays we detected a decrease in
binding when comparing 125I-TTR L55P alone to 125I-TTR L55P
mixed with the different cold TTR concentrations, which may
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reflect interference from the 125I atom. On the contrary, WT TTR
clearly bound A-Beta peptide as concluded by the increased level
of competition between 125I-TTR and increasing cold TTR
concentrations (figure 2).
After drug pre-incubation with TTR L55P we observed
increased TTR/A-Beta interaction using DCPA, DFPB, Resv
and DNP similarly to the positive control (I-Dif) (figure 3B).
However, Dif (negative control) and EGCG persisted failing to
produce any effect (figure 3B), as well as other compounds such as
flufenamic acid, genistein, benzo and TIP (data not shown).
For some of the compounds, being particularly pronounced for
DCPA, there is a marked increase in binding at higher
Figure 1. Differences in binding to A-Beta peptide by WT, T119M and L55P TTRs variant using quantitative assays. A- Immunodot
blot of A-Beta alone or mixed with WT TTR, T119M or L55P TTR, incubated at 37uC for different periods of time, and analyzed with the anti-oligomeric
antibody A11. WT and T119M TTRs interfered with A-Beta oligomerization resulting prolonged presence of oligomers, compared to A-Beta alone
which evolved to aggregates and fibrils. In opposition, L55P TTR had impaired ability to avoid fibrillization of the peptide. B- Caspase 3 activation in
SH-SY5Y cells. A-Beta without or with TTR (WT TTR, T119M or L55P TTR) incubated at 4uC for 48 h, was then added to SH-SY5Y cultured cells and
further incubated for another 48 h at 37uC. A-Beta was used at a final concentration of 10 mM and TTR at 2 mM. Significant caspase 3 activation was
observed in the presence of A-Beta peptide alone and when pre-incubated with L55P TTR. WT and T119M were able to protect against A-Beta toxicity
and lower levels of caspase 3, similar to untreated cells, were observed. a,b,cp,0,001
doi:10.1371/journal.pone.0045368.g001
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concentrations (100x). Usually, this high concentration is used to
assess non-specific binding.
b. Effect of TTR stabilizers in A-Beta proteolysis. It has
been previously shown in our laboratory that TTR is able to
proteolytically process the A-Beta peptide, contributing to
reduction of its toxicity, as the generated peptides are less
amyloidogenic than the full-length peptide [7]. This finding
suggested A-Beta proteolysis by TTR as a protective mechanism in
AD.
Because it is not known if binding to A-Beta peptide and its
degradation by TTR is part of the same protective mechanism, it
was important to assess the impact of the above selected drugs on
TTR ability to degrade A-Beta, thus ascertaining if TTR stability
is directly related to its proteolytic function.
Using a fluorescent peptide containing part of the A-Beta
sequence and one of the TTR cleavage sites described for A-Beta
[7], we observed that only DCPA and DFPB showed increase of
15% in TTR proteolytic ability to degrade A-Beta peptide
(figure 3C) whereas the remaining, like I-Dif, DNP (figure 3C),
Dif, Resv, EGCG, flufenamic acid, genistein, benzo and TIP,
produced no effect (data not shown).
Our results suggested TTR stability as a key factor in the
interaction with A-Beta. Proteolysis can also be modulated by
small compounds known to affect TTR stability/aggregation;
however, different drugs have different effects at the binding and
at the proteolysis levels, suggesting that these are separate events or
that the TTR regions involved, in the two activities, are different.
3. Effect of TTR natural ligands on TTR binding to A-Beta
and impact in A-Beta proteolysis
Previous work by competition binding assays showed that A-
Beta peptide did not compete with T4 for binding to TTR [6];
here we show that, on the contrary, A-Beta displayed decreased
binding to TTR saturated with RBP, as no significant competition
was observed between 125I-WT TTR and cold (WT TTR+RBP)
(figure 4A).
We next investigated the impact of the natural ligands (i.e. T4
and RBP) in the proteolytic capacity of TTR to degrade A-Beta
peptide. We found that T4 did not affect the TTR ability to cleave
A-Beta peptide; in contrast, when TTR is complexed with RBP, it
drastically reduced its capacity to cleave A-Beta peptide, in as
much as 82% (figure 4B).
Discussion
Apart from its function as a carrier of T4 and retinol, TTR has
taken more recently a very important role in amyloidogenic
diseases and it is one of the 30 human proteins associated with
amyloidosis, in particularly FAP. Although, clinically, TTR
concentration in serum can be utilized as a marker of nutrition-
al/inflammatory status [24] its reduction in CSF and plasma has
been associated with AD development [25,26]. In fact, TTR has
been described as the major A-Beta binding protein in CSF
avoiding its aggregation and toxicity [27,28]. Furthermore,
investigation using in vivo models has established TTR as a
survival molecule since increased levels of TTR are observed in
transgenic mice for APP [29]. Moreover, disruption of the TTR
gene results in increased and earlier A-Beta deposition [5].
However, the mechanism by which TTR protects against A-Beta
toxicity, the pathways and molecules involved are not identified.
Recently, we proposed that TTR can proteolytically process A-
Beta peptide, generating smaller and less amyloidogenic new
peptides enabling cells to eliminate them [7].
Previous work, using qualitative assays, established that different
TTR variants bind A-Beta peptide with different affinities;
however no differences were found in their capacity to avoid A-
Beta aggregation. In the present work, using quantitative assays,
we showed differences between WT and T119M TTR and the less
stable L55P TTR mutant regarding their interaction with A-Beta.
We described that L55P TTR, contrarily to the WT and T119M
counterparts, when incubated with A-Beta peptide was not able to
prevent A-Beta aggregation and fibrillization; in addition, this
variant was also not capable of avoiding A-Beta oligomers toxicity.
One of the therapeutic strategies for TTR-related amyloidosis
aims at stabilizing the TTR tetrameric fold using small molecules
which can either i) bind the T4 binding central channel or ii) bind
outside the T4 binding channel. In group I, drugs such as
iododiflunisal [18], TIP [30], DCPA and DFPB (Almeida, MR.,
personal communication, 2011), diclonisal [31], benzoxazole,
DES [32], flufenamic acid [33,34], DNP [35] and genistein [36]
have been identified. Previous work by Cardoso et al [22] showed
that TTR stabilization may be achieved by mechanisms other that
binding to the T4 channel (group II) and compounds such as
diclofenac [18], resveratrol [32], diflunisal [18], daidzein [37] were
identified to avoid TTR aggregation in cellular studies [22] and in
in vivo studies using an FAP mice model [38,39].
We reasoned that stabilization of TTR by these two types of
compounds could also improve binding to A-Beta. If true, poor
TTR/A-Beta binding of L55P TTR would be rescued by TTR
stabilizing drugs. For compounds belonging to group I, we used I-
Dif and Dif as controls, positive and negative, respectively. Our
hypothesis was confirmed as, in fact, DCPA - a strong T4
competitor - was also able to significantly improve TTR/A-Beta
binding. We also investigated the effect of drugs belonging to
group II (non-T4 competing drugs) on TTR/A-Beta binding and
found, among the compounds tested that resv also increased
TTR/A-Beta interaction, further confirming our hypothesis.
DFPB was shown to compete moderately with T4 for TTR
binding (Almeida M.R., personal communication, 2011), but was
able to improve TTR/A-Beta interaction as much as DCPA and
I-Dif. DFPB has been shown to greatly avoid TTR aggregation
using a cellular model [22], however, by IEF, DFPB does not
Figure 2. Effect of small compounds on WT TTR binding to A-
Beta peptide. A-beta peptide immobilized onto a microtiter plate was
incubated with a constant amount of 125I-WT TTR and increasing
concentrations of unlabeled WT TTR, and binding was evaluated.
Alternatively and to investigate the ability certain compounds to
improve TTR/A-Beta interaction, unlabeled TTR was pre-incubated with
I-Dif or Dif, and further added to the immobilized A-Beta peptide. I-Dif,
but not Dif, was able to improve TTR/A-Beta interaction. ap,0.05;
bp,0.05; cp,0.05, dp,0.05.
doi:10.1371/journal.pone.0045368.g002
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produce the expected increase in tetramer/monomer TTR ratio
[22] and thus its TTR-stabilizing properties must be tetramer-
independent. To further understand how DFPB stabilizes TTR, it
is important to determine the structure of the complex.
Recently, it has been shown that EGCG is able to avoid TTR
aggregation in vitro and in vivo [40,41] and to disaggregate pre-
formed TTR amyloid fibrils [23]. Although EGCG does not
compete with T4, its binding at the surface of the protein results in
TTR tetrameric stabilization as assessed by IEF [40]. In fact,
Miyata et al. determined the crystal structure of the EGCG-V30M
TTR complex and showed that there are three EGCG binding
sites in TTR that are not related with T4 binding sites. Although, it
is not clear which residues are crucial for EGCG/TTR binding,
they described that EGCG binds in the interface of both dimers,
resulting in stabilization of the tetramer [42]. In the present
studies, EGCG as well as other tested compounds had no effect or
even worsened TTR/A-Beta binding, which can be explained if
these drugs bind in or near the A-Beta binding in TTR, thus
masking their ability to improve TTR stability and consequent
increase in A-Beta binding.
To further ascertain the influence of stability in the role of TTR
in AD, namely on proteolysis, we quantified TTR proteolytic
activity after incubation with a fluorogenic peptide encompassing
6 residues of the A-Beta peptide sequence containing one of the
TTR cleavage sites as previously described [7]. In our assay, only
DCPA and DFPB facilitated A-Beta proteolysis by TTR, raising
the hypothesis that binding and proteolysis are two distinct
mechanisms through which TTR protects against AD. At this
point there is no information neither on the TTR region that binds
A-Beta nor on the residues important for its proteolytic activity,
which was firstly described for ApoAI [19] and more recently for
NPY [43]. Possibly, the two events are directly related, and
depend on each other (for instance binding preceding proteolysis),
but with different regions of the TTR molecule responsible for the
two activities.
TTR natural ligands showed different effects in TTR binding
and proteolytic activity towards A-Beta peptide. While T4 did not
affect TTR/A-Beta interaction [6] and TTR proteolytic activity,
RBP not only prevented TTR binding to A-Beta but also
abolished TTR ability to cleave the peptide. Liz et al. using a
fluorogenic substrate corresponding to an apoA-I fragment
encompassing amino acid residues 223–228, established that while
TTR proteolytic activity was only slightly affected when
complexed with T4, TTR complexed to RBP lost its proteolytic
activity [19]. Because not all TTR is bound to RBP (the ratio
RBP: TTR in plasma is approximately 0.3 in healthy individuals
indicating that most of the circulating TTR remains free of ligand
[44,45]), it is expected that TTR proteolytic activity is not affected
by RBP in vivo.
In summary, this work showed that mutations in TTR affect its
ability to bind A-Beta peptide, interfere with A-Beta aggregation,
and its noxious effects, at the cellular level. TTR protection in AD
is probably dependent on its stability, and although genetic tests
performed so far did not reveal mutations in the TTR gene of AD
patients [46], destabilization of the protein may result from other
events, such as metal ions concentration and interaction with other
proteins. Small compounds known as TTR tetrameric stabilizers
are able to improve TTR/A-Beta interaction; proteolysis also
Figure 3. Effect of small compounds on L55P TTR binding to A-Beta peptide and consequences in TTR proteolytic activity. A-IEF
analysis of L55P alone or in the presence of different compounds known as TTR stabilizers. Similarly to previous results obtained with WT and V30M
TTR (22, 23), DCPA and I-Dif were able to stabilize the L55P fold, resulting in increased amounts of tetramer and decreased quantity of monomer;
compounds such as DFPB, DNP, Resv, EGCG and Dif did not produce any effect and levels of tetramer and monomer were similar to the L55P protein
alone. B- A-beta peptide immobilized onto a microtiter plate was incubated with a constant amount of 125I-L55P TTR and increasing concentrations
of unlabeled L55P TTR, and binding was evaluated. Alternatively and to investigate the ability certain compounds to improve TTR/A-Beta interaction,
unlabeled TTR was pre-incubated with I-Dif or Dif, EGCG, resv, DNP, DCPA and DFPB, and further added to the immobilized A-Beta peptide. Using this
variant, I-Dif, Resv, DNP, DCPA and DFPB were selected as improving TTR/A-Beta interaction, whereas Dif, EGCG and DES had no effect. ap,0.05;
bp,0.05; cp,0.05. C- Effects of selected compounds on A-Beta proteolysis by TTR, showing that DCPA and DFPB improved the TTR proteolytic
activity by approximately 15%, whereas other compounds such as I-Dif and DNP produced no effect. a,bp,0.05
doi:10.1371/journal.pone.0045368.g003
Figure 4. Effect of RBP on TTR binding to A-Beta peptide and
consequences of T4 and RBP in TTR proteolytic activity. A -
Competition binding assay between A-Beta and 125I-TTR in the
presence of increasing concentrations of cold TTR or cold TTR saturated
with RBP, showing that the presence of RBP abrogated binding. B-
Effect of T4 and RBP in A-Beta degradation by TTR using a fluorescent
peptide containing an A-Beta sequence. Similarly to binding, TTR
proteolytic activity is abolished in the presence of RBP, while T4 does
not interfere with this activity.
doi:10.1371/journal.pone.0045368.g004
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participates in TTR protection against A-Beta toxicity and may
also be modulated by small TTR stabilizers.
These results may be of relevance for the design of therapeutic
drugs that might improve TTR/A-Beta binding and TTR
proteolytic capacity to decrease or inhibit A-Beta deposition in
AD.
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